Nintedanib treatment for bleomycin-induced lung injury - First report
Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2023-01-01
|
| Edice: | Respiratory Medicine Case Reports |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2213007123001168 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|